Rayonier Advanced Materials Inc. (RYAM) Q2 2025 Earnings Conference Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals declining financial metrics, including a significant operating loss and reduced revenues across all segments, exacerbated by tariffs and operational challenges. The Q&A section highlights uncertainties in timelines and unclear management responses, which may further concern investors. Despite some positive elements like potential tariff benefits and future product commercialization, the immediate outlook is bleak, especially with reduced EBITDA guidance and negative cash flow. These factors suggest a negative stock price reaction over the next two weeks.
Key Financial Performance
Revenue $340 million, down $79 million year-over-year. The decline was driven by lower sales volumes due to tariff-related disruptions, operational challenges, and macroeconomic headwinds.
Operating Loss $1 million, declining by $29 million compared to the prior year. This was influenced by lower sales volumes, higher input costs, and operational disruptions.
Adjusted Free Cash Flow Negative $52 million year-to-date. This reflects the impact of operational challenges and lower sales volumes.
Adjusted EBITDA $28 million, a $40 million decrease compared to the second quarter of last year. The decline was driven by lower sales volumes, higher input costs, and operational challenges.
Cellulose Specialties (CS) Revenue $208 million, a decrease of $33 million year-over-year. Sales prices increased by 3%, but sales volumes declined by 15% due to tariff-related order pauses, operational challenges, and labor strikes.
Biomaterials Revenue $6 million, a decline of $2 million year-over-year. This was caused by operational challenges and labor strikes limiting feedstock availability.
Cellulose Commodities Revenue $59 million, a decrease of $26 million year-over-year. Sales volumes declined by 33% due to lower non-fluff commodity sales and operational challenges, partially offset by a 7% increase in sales prices.
Paperboard Revenue $47 million, a decline of $13 million year-over-year. Sales volumes decreased by 23%, and prices declined by 3% due to product mix and increased competition.
High-yield Pulp Revenue $29 million, a decrease of $4 million year-over-year. Sales prices declined by 11%, and sales volumes reduced by 7% due to oversupply conditions and shipment delays.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New dissolving wood pulp fluff product: RYAM is trialing a new dissolving wood pulp fluff product to address the 10% tariff on fluff pulp into China and expand sales into non-tariff regions.
Biomaterials initiatives: RYAM is advancing biomaterials projects, including bioethanol production, prebiotics, and crude tall oil facilities, with high ROI potential. The Tartas bioethanol project alone is expected to generate $8-$10 million in EBITDA annually.
Tariff-related impacts and recovery: RYAM faced $21 million in EBITDA headwinds due to tariffs but has largely resolved these issues. Chinese tariffs on cellulose specialty and dissolving wood pulp exports have been removed, and U.S. tariffs on EU and Brazilian imports enhance RYAM's competitive positioning.
Cellulose specialty market growth: The cellulose specialty market is expected to grow by 80,000 metric tons over the next two years, with RYAM positioned to capture a significant share due to its excess capacity.
Operational disruptions: RYAM faced $18 million in EBITDA headwinds due to labor strikes, power outages, and equipment issues. These issues have largely been resolved, with facilities returning to normalized operations.
Cost reduction initiatives: RYAM is targeting $10 million in corporate expense reductions and $20 million in operational savings through automation, efficiency improvements, and targeted capital investments.
Divestiture of noncore assets: RYAM plans to divest its paperboard and high-yield pulp businesses, aiming to focus on core cellulose specialties and biomaterials. Expected proceeds of $180 million will strengthen financial flexibility.
Biomaterials strategy: RYAM is leveraging its existing infrastructure to develop high-value biomaterials, including biofuels and biogenic CO2, with strong financial returns and strategic partnerships.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff-related uncertainty: Negatively impacted EBITDA by approximately $21 million, with $7 million tied to direct disruptions and $14 million due to customers' reduced access to key markets. While some recovery is expected, indirect effects remain a challenge.
Foreign exchange revaluations: Resulted in $8 million in losses due to U.S. dollar weakness, though it may provide a competitive advantage in the long term.
Operational disruptions: Accounted for $18 million in EBITDA headwinds, including labor strikes, power outages, severe winter disruptions, and equipment issues. These disruptions have largely been resolved.
Noncash environmental charges: Incurred $12 million in charges related to legacy site remediation responsibilities, with no immediate cash impact.
Paperboard and high-yield pulp softness: Higher-than-expected softness in these segments led to reduced profitability, with ongoing efforts to mitigate exposure.
Temiscaming operational challenges: Soft market conditions and custodial site expenses led to breakeven or slight EBITDA losses. Plans are in place to restore profitability through cost reductions and efficiency improvements.
Tariff impacts on cellulose specialties: Chinese tariffs caused short-term order disruptions, though most impacts have been resolved. Fluff pulp exports to China still face a 10% tariff.
Labor strikes and production issues: Strikes at Tartas and other operational challenges caused significant production losses, though these issues are now largely resolved.
High-yield pulp market oversupply: Continued oversupply conditions in China and macroeconomic headwinds have negatively impacted pricing and volumes.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 EBITDA Guidance: Revised down to $150 million to $160 million from the initial $215 million to $235 million due to extraordinary and nonrecurring challenges.
2026 and Beyond EBITDA Growth: Expected to nearly double EBITDA over the next two years relative to revised 2025 guidance, driven by normalized cellulose specialty orders, cost reductions, and strategic growth investments.
Tariff Impact: $21 million negative impact on 2025 EBITDA, with $7 million expected to recover as trade policies stabilize. Remaining $14 million indirect effects are not assumed to recover in the current forecast period.
Operational Challenges: $18 million EBITDA headwinds in 2025 due to labor strikes, power outages, and equipment issues. These issues are largely resolved, with normalized operations expected moving forward.
Biomaterials Initiatives: Projected to generate significant EBITDA growth through projects like bioethanol production and other high-return investments, with a pipeline of projects expected to yield strong returns.
Divestiture of Noncore Assets: Plans to divest paperboard and high-yield pulp businesses, aiming to strengthen financial position and focus on core cellulose specialties and biomaterials.
Cellulose Specialties Market: Anticipated annual price increases of 4% to 6% due to strong supply-demand dynamics and industry consolidation, supporting margin expansion.
Cost Reduction Initiatives: Targeting $10 million in corporate expense reductions and $20 million in operational savings through automation and efficiency improvements.
2027 Core EBITDA Target: Aiming for a normalized core EBITDA run rate of approximately $308 million by the end of 2027, increasing to $338 million with the AGE project in 2028.
Biomaterials Project Pipeline: Future projects expected to generate $39 million in annual EBITDA with high equity returns, including bioethanol and CTO facilities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the timeline for the dissolving wood pulp fluff product approval in China and its impact on EBITDA?
A:The product is currently undergoing trials and qualifications with Chinese customers. If successful, commercialization is expected by 2026. The cost to produce this product is slightly higher due to higher purity levels, but the company expects to recapture most, if not all, of its market share lost due to the current 10% tariff in China.
Q:Is the $24 million capital for structural cost reduction initiatives entirely for 2026, and what is the timing for the $30 million target?
A:Most of the $24 million capital will be spent in 2025, and the $30 million value will be realized in 2026. The company expects to be positioned to achieve these savings as they enter 2026.
Q:What is the timeline for the new product initiatives at Temiscaming?
A:The freezer board and oil and grease board products are expected to be commercialized in 2026 after customer trials. The high-yield pulp softwood rolls product is targeted for introduction in Q1 2026, with trials expected to be completed in Q4 2025. A significant portion of the $35 million benefit is tied to these new product developments.
Q:What would need to happen to outperform the $30 million incremental EBITDA forecast for cellulose specialties by 2027?
A:The $30 million growth is tied to substituting cellulose specialties for commodities, with an expected volume increase of 15,000 tons per year and a pricing differential of $1,000 per ton. Outperformance would require exceeding these growth and pricing assumptions.
Q:How will capital be allocated in 2027 given the $140 million free cash flow forecast?
A:The focus will be on high-return projects, such as eSAF and bioethanol to jet opportunities. The company also aims to pay down 5% of the principal debt annually. Returning capital to shareholders is a lower priority unless project returns diminish.
Q:What is the timeline for achieving the $30 million cost reduction run rate?
A:The company expects to achieve the $30 million run rate as they enter 2026, with most investments needed for this already completed or being completed by the end of 2025.
Q:How will the company benefit from the 15% and 50% tariffs on EU and Brazilian imports?
A:The company plans to leverage the tariffs to strengthen its competitive position in the U.S. market, potentially defending market share and increasing margins. Pricing strategy will focus on inflation-plus pricing rather than aggressive price cuts.
Q:What is the strategy for entering the biomaterials market, and how confident is the company in its ramp-up?
A:The company is confident in its ability to construct facilities and commercialize products by 2028. Entry into markets like CTO and bioethanol is supported by commercial agreements secured before production begins, ensuring market access without significant price sacrifices.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific EBITDA impact of the dissolving wood pulp fluff product, citing difficulty in quantifying the increase. Additionally, while discussing the $35 million benefit tied to new product development, they acknowledged that not all of it might be realized in 2026, but did not provide a clear breakdown of expected contributions or timelines for the remaining portion.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AGE
Borregaard
RYAM equity
Slide
Tartas
Temiscaming
advantage
analyst
asset base
automation
challenge
charge
driver
dynamic
efficiency
headwind
import tariff
industry
infrastructure
market valuation
multiple
nature
paperboard yield
portion
position
positioning
rate
return
shareholder value
specialty market
tariff disruption
ton
trade
uncertainty
value creation
wood pulp
year
yield pulp
RYAM Transcript
Rayonier Advanced Materials Inc. (RYAM) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call summary reveals strong financial performance, with revenue, gross margin, net income, and operating cash flow all showing significant year-over-year increases. This indicates effective cost management and operational efficiencies. Despite the lack of discussion on strategic initiatives and risks, the financial metrics alone suggest a positive sentiment. The absence of negative insights from the Q&A further supports this view. Given these factors, the stock price is likely to experience a positive movement in the next two weeks.
Rayonier Advanced Materials Inc. (RYAM) Q4 2025 Earnings Call Transcript
Unknown3-4
The earnings call presents a mixed outlook: while there are plans for substantial EBITDA improvement and price increases, guidance has been lowered, and there are challenges in the cellulose market. The Q&A reveals optimism from management but lacks clarity on key issues, such as rejected offers and trade duties impact. No new partnerships or strong financial metrics were highlighted, and the guidance cut may weigh on sentiment. Thus, the stock is likely to remain neutral over the next two weeks.
Rayonier Advanced Materials Inc. (RYAM) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call presents a mixed picture. While there are positive aspects like improved margins in Cellulose Specialties and cost reduction initiatives, challenges such as reduced EBITDA guidance, significant declines in Paperboard and High-Yield Pulp EBITDA, and unresolved issues in the Q&A session weigh heavily. The market is likely to react negatively due to the lowered 2025 guidance, operational challenges, and uncertainty in key business areas, despite some optimistic long-term projections.
Rayonier Advanced Materials Inc. (RYAM) Q2 2025 Earnings Conference Call Transcript
Unknown8-6
The earnings call reveals declining financial metrics, including a significant operating loss and reduced revenues across all segments, exacerbated by tariffs and operational challenges. The Q&A section highlights uncertainties in timelines and unclear management responses, which may further concern investors. Despite some positive elements like potential tariff benefits and future product commercialization, the immediate outlook is bleak, especially with reduced EBITDA guidance and negative cash flow. These factors suggest a negative stock price reaction over the next two weeks.
RYAM Slides
RYAM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
